Data firm sees 2011 drug sales rising 5-7 percent

Oct 07, 2010 By LINDA A. JOHNSON , AP Business Writer

(AP) -- Revenue from global prescription drug sales should increase 5 percent to 7 percent next year, reaching at least $880 billion, fueled by new drugs and rising sales in developing countries, according to drug data firm IMS Health.

The company's annual forecast sees the market recovering a bit from this year, when are on pace to total about $845 billion, up just 4 percent to 5 percent over 2008. That was the lowest growth rate over the past decade, when sales jumped 6 percent to 12 percent each year.

The IMS Market Prognosis report attributes the expected revenue increase to the anticipated launch of new potential blockbusters, rising in about two dozen of the top developed and emerging markets, and strong economic growth in China and other emerging markets, which are spending more on health care.

"China is out in front" in prescription drug sales growth, said Murray Aitken, an IMS Health senior vice president. "It will grow, we expect, 25 percent next year."

That will move China past Germany to become the world's third-largest pharmaceutical market, with more than $50 billion in sales next year.

Spending on next year is expected to rise, on average, about 16 percent in China and 16 other emerging countries now heavily targeted by drugmakers. That's because their governments have been increasing their spending on health care and they have a growing middle class that can afford more medicines.

Those countries each are expected to increase annual spending on prescription drugs by at least $1 billion by 2015. For instance, the lowest spender in the group, Vietnam, would double its drug expenditures, from $1 billion this year to $2 billion in 2015.

Prescription sales will grow far less in developed markets because insurers and government health programs, particularly in Europe and the U.S., are working to hold down what they spend on prescription drugs. Strategies include requiring pre-authorizations for more medications, saddling patients with bigger copayments and, in some European countries, reducing reimbursement levels.

Prescription revenues in Canada and in Europe's five biggest markets - Germany, France, Italy, Spain and the United Kingdom - will grow at just 1 percent to 3 percent next year, IMS forecasts. In the U.S., the world's biggest pharmaceutical market, growth is expected to be about 4 percent, for a total of about $325 billion next year.

Prices the companies charge will stay in line with this year's levels, IMS said.

The report notes new drugs are coming that could bring big advances against diseases in which patients need better treatments, from skin cancer and stroke prevention to multiple sclerosis and hepatitis C.

Meanwhile, new generic competition is on the way for some blockbuster drugs, as medicines with sales totaling more than $30 billion just in the world's top eight markets lose patent protection by the end of 2011. Those include a number of what Aitken called "iconic products," such as cholesterol fighter Lipitor, the world's top-selling drug; antipsychotic drug Zyprexa; and antibiotic Levaquin. Anticlotting drug Plavix, the world's No. 2 seller, is expected to face generic competition in May 2012.

"We're seeing the end of an era," said Aitken, adding, "Much of the impact won't be felt until 2012 (when) there'll be another raft of products losing exclusivity."

The IMS report is in line with what executives at many top drugmakers have been saying for a few years now about their plans to wring more sales out of emerging markets. Most are adding more sales representatives and building new research facilities and low-cost factories in those countries.

But Merck Chief Financial Officer Peter Kellogg, speaking Tuesday at a conference of pharmaceutical and health care analysts, cautioned that rapid sales growth in those countries is not a sure thing.

"Emerging markets are very small today from a pharmaceutical sales standpoint," Kellogg said, according to a transcript. "Just as an example, in China, the top Western pharmaceutical company only has about a 3 percent or 4 percent market share of the total therapeutics in that market."

Explore further: Judge blocks Massachusetts ban on painkiller

1 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

US prescription drug use fell in 2008, study says

May 13, 2009

(AP) -- Prescription drug use in the U.S. fell last year, although total spending on drugs increased as prices rose sharply on brand-name products, pharmacy benefits manager Medco Health Solutions said Wednesday.

Record 12 pct drop for PC sales in 2009: Gartner

Mar 02, 2009

Sales of personal computers are expected to decline by 11.9 percent to 257 million units in 2009, the steepest drop in the industry's history, market research firm Gartner said Monday.

PC maker Lenovo turns to profit on China sales

Aug 19, 2010

(AP) -- Lenovo Group, the fourth-largest personal computer maker, said Thursday it rebounded to a quarterly profit from a loss a year earlier, driven by strong sales in China and other emerging markets.

PC sales to grow 20 percent in 2010: Gartner

Mar 04, 2010

Worldwide sales of personal computers are expected to grow nearly 20 percent this year over 2009, with laptops driving new sales, research group Gartner said on Thursday.

Strong sales not leading to mobile profits

Jan 26, 2006

Mobile-phone manufacturers are finding that global demand for handsets is almost insatiable, as consumers in wealthy countries flock to update their phones with the latest multi-functioning products, while those in poorer ...

Recommended for you

FDA approves new type 2 diabetes drug

11 hours ago

(HealthDay)—Millions of Americans with type 2 diabetes have a new treatment option with the U.S. Food and Drug Administration's approval Tuesday of a once-weekly injectable drug, Tanzeum.

AAFP provides tips to address patients' vaccine concerns

Apr 14, 2014

(HealthDay)—Physicians remain the biggest influence on whether patients get vaccinated, and must be prepared to address patients' reservations, according to an article published in the March/April issue ...

Tamiflu and Relenza: How effective are they?

Apr 11, 2014

Tamiflu (the antiviral drug oseltamivir) shortens symptoms of influenza by half a day, but there is no good evidence to support claims that it reduces admissions to hospital or complications of influenza. This is according ...

User comments : 0

More news stories

Low Vitamin D may not be a culprit in menopause symptoms

A new study from the Women's Health Initiative (WHI) shows no significant connection between vitamin D levels and menopause symptoms. The study was published online today in Menopause, the journal of The North American Menopa ...

Patent talk: Google sharpens contact lens vision

( —A report from Patent Bolt brings us one step closer to what Google may have in mind in developing smart contact lenses. According to the discussion Google is interested in the concept of contact ...

Wireless industry makes anti-theft commitment

A trade group for wireless providers said Tuesday that the biggest mobile device manufacturers and carriers will soon put anti-theft tools on the gadgets to try to deter rampant smartphone theft.